These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose. Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. Skulberg AK; Åsberg A; Khiabani HZ; Røstad H; Tylleskar I; Dale O Addiction; 2019 May; 114(5):859-867. PubMed ID: 30644628 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. Vanky E; Hellmundt L; Bondesson U; Eksborg S; Lundeberg S Acta Anaesthesiol Scand; 2017 Jul; 61(6):636-640. PubMed ID: 28444856 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. Mundin G; McDonald R; Smith K; Harris S; Strang J Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Dowling J; Isbister GK; Kirkpatrick CM; Naidoo D; Graudins A Ther Drug Monit; 2008 Aug; 30(4):490-6. PubMed ID: 18641540 [TBL] [Abstract][Full Text] [Related]
10. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a new, nasal formulation of naloxone. Tylleskar I; Skulberg AK; Nilsen T; Skarra S; Jansook P; Dale O Eur J Clin Pharmacol; 2017 May; 73(5):555-562. PubMed ID: 28144724 [TBL] [Abstract][Full Text] [Related]
12. Bioavailability investigation of a new tilidine/naloxone liquid formulation compared to a reference formulation. Martin W; Ring J; Gaupp M; Arnold P; Sennewald R; Doser K Arzneimittelforschung; 1999 Jul; 49(7):599-607. PubMed ID: 10442208 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device. Krieter PA; Chiang CN; Gyaw S; McCann DJ J Clin Pharmacol; 2019 Aug; 59(8):1078-1084. PubMed ID: 30861160 [TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Ryan SA; Dunne RB Pain Manag; 2018 May; 8(3):231-245. PubMed ID: 29683378 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. Krieter P; Chiang CN; Gyaw S; Skolnick P; Snyder R Drug Metab Dispos; 2019 Jul; 47(7):690-698. PubMed ID: 30992306 [TBL] [Abstract][Full Text] [Related]
17. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. Kinzler ER; Pantaleon C; Iverson M; Aigner S Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694 [TBL] [Abstract][Full Text] [Related]
18. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. McDonald R; Danielsson Glende Ø; Dale O; Strang J Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483 [TBL] [Abstract][Full Text] [Related]
19. Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. Gufford BT; Ainslie GR; White JR; Layton ME; Padowski JM; Pollack GM; Paine MF Clin Transl Sci; 2017 Sep; 10(5):380-386. PubMed ID: 28504483 [TBL] [Abstract][Full Text] [Related]
20. Intranasal naloxone administration for treatment of opioid overdose. Robinson A; Wermeling DP Am J Health Syst Pharm; 2014 Dec; 71(24):2129-35. PubMed ID: 25465584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]